r the expansion 
of 225Ac production during 2023. In June, a 
strategic 
partnership 
was 
agreed 
with 
TerraPower Isotopes, to initiate the small-scale 
production of 225Ac for clinical trials in 2024, with a view to develop large-scale supply of the 
radioisotope over the longer term. Post-period 
end saw PanTera reach a capacity reservation 
agreement with Bayer and another undisclosed 
customer, both initiating in the second half of 
2024 and the company is working actively on 
several more partnerships.